<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652518</url>
  </required_header>
  <id_info>
    <org_study_id>LYT-100-2020-02</org_study_id>
    <nct_id>NCT04652518</nct_id>
  </id_info>
  <brief_title>LYT-100 in Post-acute COVID-19 Respiratory Disease</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled Safety and Efficacy Trial of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PureTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PureTech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, parallel arm study to evaluate the safety and&#xD;
      efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory&#xD;
      complications&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, parallel arm study being conducted at up to 20&#xD;
      centers globally to evaluate the safety and efficacy of LYT-100 compared to placebo in 168&#xD;
      adults with post-acute COVID-19 respiratory complications who were treated with, but no&#xD;
      longer require mechanical ventilation, extracorporeal membrane oxygenation, non-invasive&#xD;
      ventilation (eg CPAP or BiPAP), high-flow nasal oxygen therapy, or combination thereof.&#xD;
      LYT-100 or placebo will be taken daily for up to 91 days with the primary outcome of change&#xD;
      in distance walked on the six-minute walk test performed in line with the American Thoracic&#xD;
      Society Respiratory Society Guidelines assessed at Day 91. Secondary endpoints, including&#xD;
      pharmacokinetics, inflammatory biomarkers, imaging, and patient-reported outcomes of dyspnea&#xD;
      and the 36-Item Short Form Health Survey will also be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in distance walked on the six-minute walk test (6MWT)</measure>
    <time_frame>Baseline to Day 91</time_frame>
    <description>The 6MWT is a validated endpoint commonly used in clinical trial research</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Borg Dyspnoea Scale (mBDS) score</measure>
    <time_frame>Baseline to Day 91</time_frame>
    <description>The mBDS is an assessment tool that analyzes breathlessness under exertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment as collected using the SF-36</measure>
    <time_frame>Baseline to Day 91</time_frame>
    <description>The SF-36 (v2) is a self-administered questionnaire containing 36 items that measures functional status, well-being and overall evaluation of health in 8 domains</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>LYT-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100 taken orally BID for 91 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LYT-100 taken orally BID for 91 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100</intervention_name>
    <description>oral administration</description>
    <arm_group_label>LYT-100</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalization for COVID-19 respiratory disease (with positive result of a molecular&#xD;
             RT-qPCR diagnostic test or SARS-CoV-2 RNA result) for at least 1-day within the last&#xD;
             42 days prior to screening, and requiring at least one of the listed treatment&#xD;
             modalities: MV, ECMO, NIV, HFNO during hospitalization&#xD;
&#xD;
          -  COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan) with a minimum of two&#xD;
             lung lobes involvement&#xD;
&#xD;
          -  Able to bear weight and ambulate a minimum of 10 m distance (use of inhaled oxygen&#xD;
             permitted)&#xD;
&#xD;
          -  Shortness of breath ≥ grade 3 on mBDS dyspnea scale and not requiring MV, ECMO, NIV,&#xD;
             and/or HFNO (nasal O2 is allowed) for at least 72 hours before screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing chronic respiratory condition(s), obstructive or restrictive, for which&#xD;
             the patient is actively taking concomitant medication are excluded. Patients with&#xD;
             history of Idiopathic Pulmonary Fibrosis (IPF), lung cancer, pulmonary arterial&#xD;
             hypertension, other interstitial lung diseases, severe cardiac insufficiency (grade&#xD;
             IV) are excluded irrespective of whether they are actively being medicated for those&#xD;
             conditions or not.&#xD;
&#xD;
          -  Pre-existing co-morbid conditions preventing outcome assessments, e.g., neurological,&#xD;
             medical, orthopedic injury/disability, disease or condition that would prevent ability&#xD;
             to transfer and walk for 6 minutes, prior to confirmed COVID-19 diagnosis&#xD;
&#xD;
          -  Unstable angina or myocardial infarction in the last month prior to screening&#xD;
&#xD;
          -  Patients on MV, ECMO, NIV, and/or HFNO within the last 72 hours prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toby Maher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keck School of Medicine, University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Paden</last_name>
    <phone>617-226-4813</phone>
    <email>lyt100clinical@puretechhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California - Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-409-5383</phone>
    </contact>
    <investigator>
      <last_name>Toby Maher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>336-659-8414</phone>
    </contact>
    <investigator>
      <last_name>Barry Sigal, MD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Coordinator</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>512-459-0301</phone>
    </contact>
    <investigator>
      <last_name>Jack Bissett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul de Pneumoftiziologie &quot;Marius Nasta&quot; (&quot;Marius Nasta&quot; Pneumoftiziology Institute)</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40 (0) 21-335-69-10</phone>
    </contact>
    <investigator>
      <last_name>Florin Dumitru Milhatan, MD, PhD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute for Infectious Diseases &quot;Prof. Dr. Matei Balş&quot; (Arensia Eploratory Medicine)</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
    </contact>
    <contact_backup>
      <phone>+40 (0) 21-201-09-80</phone>
    </contact_backup>
    <investigator>
      <last_name>Adrian Streinu-Cercel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic De Pneumoftiziologie &quot;Leon Daniello&quot; Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400332</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <contact_backup>
      <phone>+40 (0) 743 434 360</phone>
    </contact_backup>
    <investigator>
      <last_name>Milena Adina Man, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40 (0) 372-273-665</phone>
    </contact>
    <investigator>
      <last_name>Mihai Olteanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes - Timisoara</name>
      <address>
        <city>Timişoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40 (0) 256-20-76-70</phone>
    </contact>
    <investigator>
      <last_name>Monica Marc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Respiratory Disease</keyword>
  <keyword>novel coronavirus</keyword>
  <keyword>respiratory complications</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>post acute</keyword>
  <keyword>lung fibrosis</keyword>
  <keyword>interstitial lung disease</keyword>
  <keyword>long COVID</keyword>
  <keyword>long haul COVID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

